Evaluating the performance characteristics of five lateral flow assays for the detection of the SARS-CoV-2 nucleocapsid antigenSARS-CoV-2 뉴클레오캡시드 항원 검출을 위한 5가지 측면 유동 분석의 성능 특성 평가Article Published on 2022-05-252022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법, [키워드] 95% CI Accuracy acquisition age assays caution Chain Reaction Characteristics China collected Community complement complementary costly COVID-19 COVID-19 negative COVID-19 pandemic diagnostic Diagnostic accuracy early diagnosis ENCODE Evaluating facilitate female FIVE hospitalised individuals with COVID-19 Infection Inpatient Italy lateral flow MHRA nucleocapsid antigen outcomes Oxygenation Participants Patient patients with COVID-19 PCR testing performed polymerase chain polymerase chain reaction protocol ranged reverse-transcriptase polymerase chain reaction Rome RT-PCR RT-PCR assay RT-PCR assays RT-PCR testing SARS-CoV-2 SARS-CoV-2 antigen sensitivity swabbing the SARS-CoV-2 thresholds variable Variation was performed WHO [DOI] 10.1038/s41598-022-12805-1 PMC 바로가기 [Article Type] Article
Control of CDH1/E-Cadherin Gene Expression and Release of a Soluble Form of E-Cadherin in SARS-CoV-2 Infected Caco-2 Intestinal Cells: Physiopathological Consequences for the Intestinal Forms of COVID-19SARS-CoV-2에 감염된 Caco-2 장 세포에서 CDH1/E-Cadherin 유전자 발현 및 가용성 형태의 E-Cadherin 방출 제어: COVID-19의 장 형태에 대한 생리병리학적 결과Article Published on 2022-05-042022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘, 치료기술, 치료제, [키워드] 24 hour 24 hours 48 hour 48 hours ACE2 ACE2 mRNA Affect AT1 Caco-2 Caco-2 cell Caco-2 cells cadherin CDH1 Cell cell line cells Co-receptor connexin consequence contributing to Control COVID-19 Culture culture supernatant diarrhoea diarrhoea) digestive tract Disruption dissemination down-regulated dysregulation E-cadherin ENCODE epithelial exposure to expresse expression form Gastrointestinal symptom gastrointestinal symptoms gastrointestinal tract HCoV HCoV-OC43 HLA class I human ACE2 illnesses in viral induce infected with SARS-CoV-2 Infection intestinal Intestinal barrier intestinal cells intestinal tissue intranasal involved JAMA junctions leads membrane mRNA mRNA expression OC43 occludin pandemic Patient Physiopathological Post-infection Protein receptor receptor ACE2 Release remained reported respiratory respiratory tract SARS-CoV-2 SARS-COV-2 infection significant increase significantly lower Symptom the disease these symptoms TMPRSS2 Transcription transgenic mice Trigger Viral viral entry virus [DOI] 10.3389/fcimb.2022.798767 PMC 바로가기 [Article Type] Article
Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque쥐 및 붉은털 원숭이에서 침팬지 아데노바이러스 기반 COVID-19 백신의 비임상 면역원성, 생체 분포 및 독성 평가Article Published on 2022-05-012022-09-12 Journal: Archives of Toxicology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome addition Adenovirus adenovirus-based biodistribution candidate vaccine caused cellular Chimpanzee Chimpanzee adenovirus vector collected conditions coronavirus COVID-19 COVID-19 vaccine develop DNA dose effective Effective vaccines elicit ENCODE evaluated full-length spike protein global pandemic Humoral response immune response immunogenicity induce injected injection Intramuscular injection intramuscularly long-lasting morbidity and mortality Neutralizing antibody response organ polymerase chain profile qPCR quantified Quantitative rhesus rhesus macaque Safe safety profile SARS-CoV-2 serotype shown T cell responses Th1 toxicology Vaccine were given [DOI] 10.1007/s00204-021-03221-x PMC 바로가기 [Article Type] Article
Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activitySARS-CoV-2 3CLpro 활성 검출을 위한 비색 분석법 개발Article Published on 2022-04-292022-09-11 Journal: Biochemical Journal [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] 3CLpro acute respiratory syndrome coronavirus assay development. AuNP causative agent cellular conditions coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 Coronavirus replication COVID COVID 19 COVID-19 detect development diagnostic diagnostic test diagnostic testing disease ENCODE exogenously expressed global pandemic gold Gold nanoparticle HEK293T highlight human cells in vitro inactive mutant peptide point-of-care protease Protease activity Protein purified respiratory SARS-CoV-2 SARS-CoV-2 genome SARS-COV-2 infection sensitivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 virus [DOI] 10.1042/BCJ20220105 PMC 바로가기 [Article Type] Article
Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions생리학적 및 병리학적 조건에서 골수 세포에서 MS4A 패밀리 구성원의 차등 발현 및 조절Article Published on 2022-04-012022-09-11 Journal: Journal of leukocyte biology [Category] MERS, 바이오마커, [키워드] Analysis Arthritis Bioinformatics analysis CD20 cellular circulating monocyte circulating monocytes circulating neutrophils COVID-19 differentially expressed ENCODE expressed expression family family members functional gene expression regulation gene family glucocorticoid Hormones immature Immunity in vitro increase in marker monocyte Monocytes monocytes/Mϕs MS4A1 MS4A14 MS4A2 MS4A3 MS4A4A MS4A4E MS4A6A MS4A7 myeloid cell myeloid cells myeloid precursors Neutrophils pathological condition patients physiological Protein Proteins regulated Regulation reported rheumatoid arthritis RT-PCR severe disease therapeutic targets tissue were expressed [DOI] 10.1002/JLB.2A0421-200R PMC 바로가기 [Article Type] Article
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report건강한 일본 성인을 대상으로 한 코로나19 백신 mRNA-1273의 1/2상 무작위 위약 대조 연구: 중간 보고서Clinical Trial Published on 2022-03-182022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered adverse event AEs age AMED anti-SARS-CoV-2 immune response antibody ARMS baseline company conducted coronavirus COVID-19 COVID-19 vaccine mRNA-1273 demonstrated development dose ENCODE enrolled fatigue geometric healthy immune response immunogenicity Injection-site pain Interim report Intramuscular injection Japan Japanese Limited mRNA vaccine mRNA-1273 myalgia NAb neutralising antibody occurred outcome participant Participants pharmaceutical Placebo placebo-controlled study placebo-controlled trial randomised receive reported Safety safety profile SARS-CoV-2 SARS-COV-2 infection secondary outcome Spike protein stratified Takeda vaccination Vaccine [DOI] 10.1016/j.vaccine.2022.02.030 PMC 바로가기 [Article Type] Clinical Trial
Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes게놈 전반에 걸친 분석을 통해 SARS-CoV-2 바이러스 유전자 Orf9c가 인간 다능성 줄기 세포 유래 심근세포에 미치는 해로운 영향을 보여줍니다Article Published on 2022-03-082022-09-11 Journal: Stem Cell Reports [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료법, [키워드] Abnormalities abnormality acute respiratory syndrome acute respiratory syndrome coronavirus ameliorated analyses Analysis Apoptosis apoptotic approved ATP ATP synthesis cardiac dysfunction cardiac injury cardiomyocyte caused Cell cellular characterized coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 death defined detrimental detrimental effect detrimental effects disease down-regulated drug Drug administration dysfunction electrical ENCODE expression Factor Factors food functional Genes Genome heart disease heart muscle human pluripotent stem cell Impact Inflammation Injury Ivermectin manifestation Manifestations meclizine meclizine. molecular mechanism molecular mechanisms Orf9c overexpression Pathways Protein Proteins Proteomic analysis reduced respiratory restored SARS-CoV-2 SARS-CoV-2 viral severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 signaling pathways significantly stem cell Therapeutic approach Transcriptomic analyses transcriptomic analysis U.S. Food and Drug Administration up-regulated [DOI] 10.1016/j.stemcr.2022.01.014 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cellsSARS-CoV-2 Nsp13은 NKG2A 발현 NK 세포의 억제를 폐지하는 HLA-E 안정화 펩티드를 암호화합니다Article Published on 2022-03-082022-09-11 Journal: Cell Reports [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] abrogate activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antigen binding Cell contribute coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Defense detect ENCODE epithelial cells HLA-E Host host defense human leukocyte antigen immune cells in vitro infected cells infections inhibitory receptor innate immune cell Innate immune cells leukocyte limit lung epithelial cell mechanism missing self. natural NK cell NK cells NKG2A non-structural protein Patient patients with COVID-19 peptide Prevent Protein respond resulting SARS-CoV-2 SARS-CoV-2 replication SARS-CoV-2-infected cell SARS-CoV-2-infected cells severe acute respiratory syndrome Coronavirus susceptible target cell target cells These data virus [DOI] 10.1016/j.celrep.2022.110503 PMC 바로가기 [Article Type] Article
COVID-19 receptor and malignant cancers: Association of CTSL expression with susceptibility to SARS-CoV-2COVID-19 수용체 및 악성 암: SARS-CoV-2에 대한 감수성과 CTSL 발현의 연관성Article Published on 2022-03-062022-09-11 Journal: International Journal of Biological Sciences [Category] SARS, 변종, [키워드] A549 ACE2 ACE2 mRNA Analysis analyzed Cancer cancer cell line cancer cell lines cancer patient Cancer patients cancer progression cancer tissue cancers conserved cordycepin Cordycepin (CD) correlated correlation COVID-19 COVID-19 disease COVID-19 pathogenesis COVID-19 severity COVID-19 treatment Critical CTSL cysteine disease domain dose ENCODE evaluate expressed expression furin glioma highest Human IHC immunohistochemistry inhibit inhibited isoform lung lung cancer lung tissue Lungs lysosomal malignant Malignant cancers modulating MONITOR mRNA expression mutant Mutation mutation rate N6, N6-dimethyladenosine (m62A) other proteases outcome Pathogenesis Patient PC3 performed predict prevalent Proteases Protein proteinase receptor regulate Regulation SARS-CoV-2 SARS-CoV-2 entry significantly survival susceptibility The CTSL gene. therapeutic potential These data tissue tissues TMPRSS2 Treatment Tumor tumor progression western blot [DOI] 10.7150/ijbs.70172 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial중국 성인을 대상으로 한 SARS-CoV-2 ARCoV mRNA 백신의 안전성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1상 시험Clinical Trial Published on 2022-03-012022-09-11 Journal: The Lancet. Microbe [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] abnormal change abnormal changes Academy administration adverse event adverse events Adverse reaction Adverse reactions All participant All participants analyses Analysis Anti-RBD IgG anti-SARS-CoV-2 Antibody titre assigned baseline block Block randomisation caused cellular immune responses China Chinese clinical testing conducted convalescent patient Convalescent patients COVID-19 pandemic development domain dose dose-escalation doses double-blind effective vaccine Effective vaccines eligible participant ELISA ELISPOT ENCODE enrolled enzyme enzyme-linked immunospot expected exploratory Fever first vaccination FIVE foundation grade 3 group groups highest hospital humoral humoral immune responses Humoral response humoral responses IFN-γ IL-2 immune immune response immune responses immunogenicity incidence individual Intramuscular injection investigators Laboratory laboratory analyses Laboratory test Laboratory tests live SARS-CoV-2 lowest majority Medical Science Medical Sciences Mild moderate mRNA vaccine natural neutralisation assays Neutralising Antibodies neutralising antibody observation outcome participant Participants peaked Phase 1 phase 1 trial Placebo placebo group placebo-controlled Primary outcome pseudovirus randomised Randomly RBD RBD IgG RBD-specific IgG receive Registered reported research and development resolved Safe Safety safety analyses safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses Science screened second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events Seven significantly Specific Specific T-cell response Spike protein Support systemic adverse event T-cell Response T-cell responses the placebo group the SARS-CoV-2 titre titres Tolerability treatment allocation Trial vaccination Vaccine vaccine dose vaccine doses were assessed were given with COVID-19 Zhejiang [DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial